RSS feed source: National Institute of Health

Notice of Special Interest (NOSI): Accelerating Malaria Vaccine and Monoclonal Antibody Discovery

The purpose of this Notice of Special Interest (NOSI) is to invite applications proposing early-phase translational research to generate new malaria vaccine candidates or monoclonal antibody (mAb)-based interventions suitable for further downstream development and clinical evaluation, particularly for Plasmodium falciparum and P. vivax.

Background

Recently, the first-generation malaria vaccine RTS,S/AS01E, and a similar vaccine, R21/Matrix M, were recommended by the World Health Organization (WHO) for broad introduction in African countries for children more than 5 months old. Additionally, emerging clinical data show that passive immunization with malaria specific mAbs could provide protection in African adults and children. To address future effective global malaria control and elimination, WHO issued revised Preferred Product Characteristics (PPC) for future malaria vaccine development calling for new strategic priorities for next generation malaria vaccines, and

Click this link to continue reading the article on the source website.

RSS feed source: National Institute of Health

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

National Institute of Allergy and Infectious Diseases (NIAID)

Funding Opportunity Title

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Activity Code

R01 Research Project Grant

Announcement Type

Related Notices

April 4, 2024 – Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084August 31, 2022 – Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.August 5, 2022 – Implementation Details for

Click this link to continue reading the article on the source website.

RSS feed source: National Institute of Health

Participating Organization(s)

Centers for Disease Control and Prevention (CDC)

 

CDC and CDC/NIOSH disclaimer:

The policies, guidelines, terms, and conditions of the HHS Centers for Disease Control and Prevention (CDC) stated in this Notice of Funding Opportunity (NOFO) might differ from those used by the HHS National Institutes of Health (NIH). If written guidance for completing this application is not available on the CDC website, then CDC will direct applicants elsewhere for that information.

Components of Participating Organizations

National Institute for Occupational Safety and Health (NIOSH)

Funding Opportunity Title

Occupational Safety and Health Training Project Grants [T03 ]

Activity Code

T03

Announcement Type

Reissue of RFA-OH-22-003

Related Notices

None

Click this link to continue reading the article on the source website.

RSS feed source: National Institute of Health

Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity

This Notice of Special Interest (NOSI) solicits research on the immunologic characterization of mice with diverse microbial experience (commonly referred to as “dirty mice”) to determine their usefulness as research tools for advancing understanding of human immune status and function during homeostasis or in infectious or immune-mediated (e.g., allergy, autoimmunity, transplant rejection) diseases.

Background

Mouse models have been critical in the study of immune system development and function, microbial pathogenesis, allergic and autoimmune diseases, providing mechanistic insights that have been foundational for the development of therapeutics and vaccines. Despite the value of mice in advancing these areas, multiple differences in immune responses between laboratory mice and humans have limited their utility for predicting human responses to candidate vaccines and immunotherapies. This discrepancy has

Click this link to continue reading the article on the source website.